Cancer immunotherapies space to witness extraordinary growth
Several late-stage pipeline drugs are expected to achieve blockbuster status by the end of 2022,
The market size for cancer immunotherapies is expected to grow more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, representing a rapid compound annual growth rate (CAGR) of 23.9%, according to business intelligence provider GBI Research.
The company’s latest report states that there are currently 2,037 products in active development in the cancer immunotherapy pipeline, equating to 37% of the entire oncology pipeline, and reflecting the strong interest in this class of therapy in product development.
Yasser Mushtaq, Senior Analyst for GBI Research, explains: “Although the cancer immunotherapy pipeline is clearly strong, a significant proportion is made up of early-stage products, namely those from the discovery stage to Phase I. This is indicative of the difficulty associated with progressing cancer immunotherapies from preclinical laboratory studies to clinical application in humans.
“The imbalance between early-stage and late-stage product development is more pronounced than typically seen in the industry, and may suggest greater difficulty than normal in developing cancer immunotherapies. However, these findings may also indicate a substantial drive to invest in early-stage cancer immunotherapy development, which could eventually filter through to late-stage product development.”
According to GBI Research, several late-stage pipeline drugs, as well as some already marketed drugs, are expected to achieve blockbuster status by the end of the forecast period, while a number of existing blockbuster therapies are forecast to experience strong revenue growth.
Established immunotherapies, particularly Revlimid, Opdivo, Keytruda and Gazyva, are set to witness rapid sales growth throughout the forecast period, with Keytruda and Opdivo rising by $7 billion and $9 billion, respectively. Revlimid will experience similar levels of growth, driven by label expansions covering oncology indications, including multiple forms of leukemia and lymphoma.
Mushtaq adds: “A number of pipeline products are also forecast to be approved by 2022, some of which are expected to be commercial successes. AstraZeneca’s durvalumab and tremelimumab, in development as individual therapies and in combination, will be the most notable products.
“Additional anticipated blockbusters by 2022 include the cancer vaccines CTL-019 (tisagenlecleucel-T) and KTE-C19 CAR, developed by Novartis and Kite Pharma, respectively.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance